4. Miles White - Abbott Laboratories

2014 pay: $17.7 million
2015 pay: $19.4 million                             

In 2015, Abbott ($ABT) said that it was keeping its eye out for potential deals. Under the careful watch of CEO Miles White, the company built on that momentum to strike some important deals in 2016.

Last summer, Abbott said that it wasn’t interested in St. Jude Medical. The company changed its tune earlier this year after announcing that it would shell out $25 million for the company to gain ground in the cardiovascular and neuromodulation markets.

"Bringing together these two great companies will create a premier medical device business and immediately advance Abbott's strategic and competitive position,” White said in April.

The acquisition also stands in contrast to another recent deal, which has played out differently. Earlier this year, Abbott said that it would pay $5.8 million for point-of-care diagnostics maker Alere. But when some of Alere’s questionable business practices came to light, Abbott voiced “serious concerns” about moving forward with the deal, the company said in April.

White has said that it would be inappropriate to comment on the pending acquisition. But Alere in April said that it rejected Abbott’s request to terminate the deal.

White’s $19.4 million pay in 2015 included a $1.9 million base salary, $6.2 million in stock awards, $6.2 million in options, $3.3 million in non-equity incentives and $1 million in “other compensation.”

- here’s Abbott Laboratories’ proxy statement

For more:
Abbott changes its tune, snatches up St. Jude in $25B deal
Abbott inks $5.8B deal for Alere to expand in point-of-care diagnostics
Abbott Absorb bioresorbable stent earns unanimous recommendation from FDA panel
Abbott to close Silicon Valley manufacturing facility at cost of 144 jobs

4. Miles White - Abbott Laboratories

Suggested Articles

Working with a joint venture established by BMS and Pfizer, Fitbit also plans to help develop educational content regarding atrial fibrillation.

A clinical trial of an artificial pancreas system showed that it was able to outperform current treatments for people with Type 1 diabetes.

Sandoz pulled the plug on its commercialization partnership with Pear Therapeutics, ending its experiment with digital treatments for substance abuse.